Literature DB >> 8459378

The value of screening for diabetes in patients with skin sepsis.

C Baynes1, S Caplan, P Hames, R Swift, S Poole, J Wadsworth, R Touquet, R S Elkeles.   

Abstract

Four hundred and eighty-two patients with spontaneous skin and superficial sepsis and 291 controls of similar age and sex underwent random capillary blood glucose measurements in order to assess whether screening for diabetes in patients presenting with skin sepsis to an Accident & Emergency Department detects a greater number of cases than that present in the background population. All subjects with a concentration > 7.8 mmol/l were subsequently followed up with a 75 g oral glucose tolerance test. Forty-two (8.7%) of the 482 skin sepsis patients had a capillary blood glucose > 7.8 mmol/l compared to eight (2.7%) of the 291 without sepsis (chi 2 = 9.71, P < 0.002). Of these, 26 of the skin sepsis group and 7 of the control group attended for follow up. Of those who attended, 13 of the skin sepsis group had an abnormal glucose tolerance test (seven diabetes, six impaired glucose tolerance-IGT) compared to two (one diabetes, one IGT) of the control group (chi 2 = 2.87, P < 0.1). The difference in cases of frank diabetes between the two groups was not statistically significant. Of the total eight diabetic cases identified, five (on direct questioning) had symptoms of hyperglycaemia (thirst, polyuria and/or weight loss) and two of the others were obese, one of whom had documented ischaemic heart disease. Thus, while most cases of diabetes in patients with skin sepsis could be detected by specifically asking about hyperglycaemic symptoms and performing a blood glucose estimation when these are present, we suggest that the screening of patients with skin sepsis over 40 years of age provides an opportunistic method of screening. This strategy should yield clinically significant numbers of abnormal cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459378      PMCID: PMC1293904          DOI: 10.1177/014107689308600311

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  13 in total

1.  The natural history of impaired glucose tolerance in the Pima Indians.

Authors:  M F Saad; W C Knowler; D J Pettitt; R G Nelson; D M Mott; P H Bennett
Journal:  N Engl J Med       Date:  1988-12-08       Impact factor: 91.245

2.  The effect of treatment of moderate hypergly- caemia on the incidence of arterial disease.

Authors:  H Keen; R J Jarrett; C Chlouverakis; D R Boyns
Journal:  Postgrad Med J       Date:  1968-12       Impact factor: 2.401

3.  Sensitivity and specificity of five screening tests for diabetes in ten countries.

Authors:  K M West; J M Kalbfleisch
Journal:  Diabetes       Date:  1971-05       Impact factor: 9.461

4.  Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes").

Authors:  R J Jarrett; H Keen; J H Fuller; M McCartney
Journal:  Diabetologia       Date:  1979-01       Impact factor: 10.122

5.  Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.

Authors:  G Sartor; B Scherstén; S Carlström; A Melander; A Nordén; G Persson
Journal:  Diabetes       Date:  1980-01       Impact factor: 9.461

Review 6.  Screening for diabetes mellitus.

Authors:  D E Singer; J H Samet; C M Coley; D M Nathan
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

Review 7.  Screening for non-insulin-dependent diabetes mellitus.

Authors:  J S Trilling
Journal:  Prim Care       Date:  1988-06       Impact factor: 2.907

8.  Limitation of fasting plasma glucose for the diagnosis of diabetes mellitus.

Authors:  R Taylor; P Zimmet
Journal:  Diabetes Care       Date:  1981 Sep-Oct       Impact factor: 19.112

9.  Assessment of laboratory methods for detection of unsuspected diabetes in primary health care.

Authors:  P O Bitzén; B Scherstén
Journal:  Scand J Prim Health Care       Date:  1986-05       Impact factor: 2.581

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.